EXTENDED REPORT

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

M Hoekstra, A E van Ede, C J Haagsma, M A F J van de Laar, T W J Huizinga, M W M Kruijsen, R F J M Laan

Ann Rheum Dis 2003;62:423–426

See end of article for authors' affiliations

Correspondence to:
Dr M Hoekstra, Department of Rheumatology, Medisch Spectrum Twente, Enschede, Postbus 50000, 7500 KA Enschede, The Netherlands; mhoekstra@introweb.nl

Accepted
19 September 2002

Objective: To study factors associated with toxicity, final dose, and efficacy of methotrexate (MTX) in patients with rheumatoid arthritis (RA).

Methods: Data were used from a randomised clinical 48 week trial on 411 patients with RA all treated with MTX, comparing folates and placebo. Logistic regression was used to study the relation between baseline variables and various dependent factors, including hepatotoxicity (alanine aminotransferase $\geq 3 \times$ upper limit of normal), MTX withdrawal, final MTX dose ≥ 15 mg/week, and MTX efficacy.

Results: Addition of folates to MTX treatment was strongly related to the lack of hepatotoxicity. Next to this, high body mass index was related to the occurrence of hepatotoxicity. Prior gastrointestinal (GI) events and younger age were related to the adverse event, diarrhoea. Hepatotoxicity and GI adverse events were the main reason for MTX withdrawal, which in turn was associated with the absence of folate supplementation, body mass index, prior GI events, and female sex. Renal function (creatinine clearance ≥ 50 ml/min) was not associated with toxicity. Reaching a final dose of MTX of ≥ 15 mg/week was related to folate supplementation and the absence of prior GI events. Efficacy of MTX treatment was associated with low disease activity at baseline, male sex, use of non-steroidal anti-inflammatory drugs (NSAIDs), and lower creatinine clearance.

Conclusions: MTX toxicity, final dose, and efficacy are influenced by folate supplementation. Baseline characteristics predicting the outcome of MTX treatment are mainly prior GI events, body mass index, sex, use of NSAIDs, and creatinine clearance.

Methotrexate (MTX) is an effective disease modifying antirheumatic drug (DMARD). Its effectiveness has been proved in placebo controlled trials and in comparison with other DMARDs.^{1–3} MTX in a weekly dose can be used for years and its use is mainly limited by toxicity.^{4–6} Renal impairment and age are generally considered risk factors for developing MTX toxicity, but studies show conflicting results.^{5–9} A rise in liver enzymes, in particular the transaminases, occurs frequently during MTX treatment.^{5–6} Dose, obesity, alcohol use, and lack of folate supplementation are considered to be associated with hepatotoxicity.^{10–11} Gastrointestinal (GI) side effects also often occur during MTX treatment.^{5–6} Folic acid supplementation reduced the occurrence of GI side effects.¹² Overall toxicity scores, including both hepatotoxicity and GI side effects, have also been reduced by the addition of folic acid.^{13–15}

Pulmonary toxicity is less common. Pre-existent pulmonary disease and age have been shown to increase the risk of pulmonary side effects,^{16–19} although one other study did not show this.²⁰ Pancytopenia was found to be related to renal impairment and central nervous system toxicity was more common in elderly patients with mild renal insufficiency.^{21–22}

Disease duration, disease activity, sex, functional class, and prior DMARD use are suggested to be related to treatment response,²³ whereas age and renal function are not.^{6–8} Supplementation with folates has raised questions about the reduced efficacy of MTX, but most studies did not show a negative effect.^{13–15 24 25}

In MTX treatment a dose-response relation exists, but the optimal dose is individually determined.^{26–27} For clinical practice it is relevant to predict toxicity, final dose, and efficacy. Therefore, we aimed at studying the relation between baseline factors and toxicity, reaching a final dose ≥ 15 mg/week, and efficacy of MTX treatment.

METHODS

Data were used from a 48 week randomised placebo controlled multicentre trial, comparing the influence of placebo, folic acid, and folic acid on the toxicity and efficacy of MTX treatment. In this randomised clinical trial (RCT), selection of patients as well as MTX treatment reflected daily rheumatological care. The primary end point of the trial was the effect of folates on MTX withdrawal due to adverse events. Four hundred and eleven patients with rheumatoid arthritis (RA) were included. Exclusion criteria were prior MTX use, a creatinine clearance < 50 ml/min (Cockcroft formula),²⁸ liver disorders, leucopenia, thrombopenia, alcohol abuse, and treatment with folic or folic acid.

MTX was started in all patients at a dose of 7.5 mg/week, and increased every six weeks by 2.5 mg to a maximum of 25 mg/week until a significant decrease in disease activity (change in disease activity score ≥ 1.08) was obtained. When adverse events occurred the MTX dose was adjusted. The action following an adverse event was indicated in the protocol. Dose adjustments at the discretion of the attending rheumatologist were allowed. Patients were randomly allocated into one of three groups receiving either folic acid (1 mg/day), folic acid (2.5 mg/week), or placebo. At a MTX dose of ≥ 15 mg/week folate doses were doubled. This study has been described in detail elsewhere.¹³

Baseline variables included folate supplementation, age (years), sex, creatinine clearance (ml/min), disease duration (months), rheumatoid factor, disease activity score (DAS),

Abbreviations: BMI, body mass index; DAS, disease activity score; DMARD, disease modifying antirheumatic drug; GI, gastrointestinal; MTX, methotrexate; RA, rheumatoid arthritis; RCT, randomised controlled trial

Table 1 Baseline demographic and clinical variables (n=411)

	Folate supplementation (n=274)	Placebo (n=137)
	Mean (standard deviation)	
Age (years)	55.4 (12.7)	57.2 (12.7)
Disease duration (months)*	42 (0–600)	49.5 (1–324)
Disease activity score	4.62 (0.94)	4.63 (0.94)
Body mass index	25.6 (4.2)	26.0 (4.1)
Serum creatinine (μmol/l)	77.4 (13.9)	77.0 (15.7)
Creatinine clearance (ml/min)	89.8 (23.1)	90.2 (28.4)
	Percentage of patients	
Rheumatoid factor (positive)	250 (91)	110 (80)
Sex (female)	189 (69)	100 (73)
Smoking	88 (32)	38 (28)
Alcohol use (>4 U/week)	101 (37)	52 (38)
NSAID use	252 (92)	125 (91)
Corticosteroid use	41 (15)	27 (20)
Prior gastrointestinal events	85 (31)	38 (28)

*Median (range).

Table 2 Most frequently reported subjective adverse events. Results are shown as No (%) of patients

Nausea	154 (37)
Headache	100 (24)
Dizziness	99 (24)
Rash	90 (22)
Fatigue/malaise	81 (20)
Abdominal pain	79 (19)
Cough	71 (17)
Stomatitis	70 (17)
Alopecia	53 (13)
Diarrhoea	43 (10)

body mass index (BMI) (kg/m²), alcohol use (>4 U/week), smoking, non-steroidal anti-inflammatory drug (NSAID) use, corticosteroid use, and prior GI events. Prior GI events included prior peptic ulcers and abdominal surgery.

The following dependent variables were studied: severe hepatotoxicity (defined as a rise in alanine aminotransferase ≥ three times the upper limit of normal, which according to the protocol rules, was a reason for MTX withdrawal), the 10 most commonly reported adverse events (nausea, dizziness, headache, rash, fatigue/malaise, abdominal pain, stomatitis, cough, alopecia, and diarrhoea), MTX withdrawal due to toxicity, reaching a final MTX dose of ≥ 15 mg/week, and efficacy.

For the analysis of efficacy we used the European League Against Rheumatism (EULAR) response criteria. A good response was defined as a DAS improvement from baseline of > 1.2 in combination with a DAS < 2.4.²⁹

Statistical analysis

Data were analysed using SPSS for Windows, version 10.0. Univariate analyses were performed. The relation between baseline variables and dependent variables was studied by a backward stepwise conditional logistic regression analysis. The independent variables in this model were selected on the basis of outcome of the univariate analyses and data from the literature. A general set of baseline variables (age, disease duration, DAS, creatinine clearance, and rheumatoid factor) was included in every analysis. A variable was excluded when the p value was ≥ 0.10. Results are given as odds ratios with 95% confidence intervals. A p value of < 0.05 is considered significant.

RESULTS

The preceding analysis of the RCT showed no differences between the two folate supplemented groups. In the present study the two groups were therefore merged. Table 1 describes the baseline characteristics. There were no significant differences in baseline variables in the folate and placebo groups. Table 2 lists the 10 most common adverse events. Table 3 gives the results of the univariate and multivariate analysis.

Hepatotoxicity leading to MTX withdrawal, was associated with absence of folate supplementation and high BMI. Severe

Table 3 Univariate and multivariate logistic regression analysis (backward stepwise conditional)

	Univariate		Multivariate	
	p Value	OR (CI)	p Value	OR (CI)
Hepatotoxicity (ALT >3×ULN)				
Folate supplementation	<0.001	0.12 (0.06 to 0.24)	<0.001	0.10 (0.04 to 0.21)
Body mass index	0.02	1.08 (1.01 to 1.16)	0.04	1.09 (1.01 to 1.17)
Adverse event: diarrhoea				
Prior GI events	0.03	2.04 (1.07 to 3.89)	0.01	2.44 (2.24 to 4.78)
Age (years)	0.01	0.97 (0.94 to 0.99)	0.02	0.96 (0.96 to 0.99)
MTX withdrawal due to toxicity				
Folate supplementation	<0.001	0.27 (0.17 to 0.44)	<0.001	0.25 (0.14 to 0.42)
Prior GI events	0.02	1.81 (1.10 to 2.98)	0.03	1.85 (1.06 to 3.25)
Body mass index	0.02	1.07 (1.01 to 1.13)	0.03	1.07 (1.01 to 1.14)
Men	0.12	0.47 (0.26 to 0.85)	0.05	0.52 (0.27 to 0.99)
DAS0	0.02	1.34 (1.04 to 1.72)	NS	
MTX dose ≥ 15 mg/week				
Folate supplementation	<0.001	3.33 (2.17 to 5.12)	<0.001	3.30 (2.08 to 5.26)
Prior GI events	0.02	0.61 (0.40 to 0.93)	0.02	0.56 (0.35 to 0.90)
Efficacy				
DAS0	<0.001	0.52 (0.40 to 0.66)	<0.001	0.53 (0.40 to 0.68)
Men	0.01	1.79 (1.16 to 2.76)	0.02	1.75 (1.08 to 2.84)
NSAIDs	NS		0.02	3.18 (1.21 to 8.38)
Creatinine clearance	0.003	0.99 (0.98 to 1.0)	0.004	0.99 (0.98 to 1.0)

OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; ULN, upper limit of normal; prior GI events, prior gastrointestinal events, including peptic ulcers and abdominal surgery; NS, not significant;

*DAS0, disease activity score at baseline.

hepatotoxicity occurred in 36/137 (26%) of the placebo group, and 11/274 (4%) of the folate group. In patients with a BMI of 20–25 hepatotoxicity occurred in 16/190 (8%), in patients with a BMI of 30–35 this occurred in 10/51 (20%). The mean BMI in this study was 25 (range 20–40).

Diarrhoea was associated with prior GI events and lower age. The other nine adverse events were not related to any of the baseline variables.

Pneumonitis and leucopenia occurred in two and three patients, respectively. These numbers were too small for reliable assessment of predictive factors.

MTX was withdrawn in 126 patients. In 91 patients this was due to toxicity (52 in the placebo group, 39 in the supplemented folate group). Absence of folate supplementation, prior GI events, and BMI are related to MTX withdrawal.

The mean final MTX dose was 17.6 mg/week in the folate group and 15.0 mg/week in the placebo group—a significant difference ($p < 0.001$). An MTX dose ≥ 15 mg/week was reached in 221 (54%) of all 441 patients. Reaching such a final “high” dose is related to folate supplementation and absence of prior GI events.

The DAS at baseline (DAS0) was associated with a good response. The probability of a good response is higher with a lower disease activity at baseline. Moreover, efficacy was better in men and in patients who used NSAIDs. In men a good response was reached in 57/121 (47%) and in women in 95/289 (33%). In the group receiving NSAIDs a good response was reached in 144/375 (38%), in contrast with 8/32 (25%) in the group who did not use NSAIDs. There was a significant inverse correlation with creatinine clearance and efficacy.

DISCUSSION

Our data show that next to folate supplementation a higher BMI is related to hepatotoxicity. Prior GI events and younger age are related to the occurrence of diarrhoea, and MTX withdrawal is related to the absence of folate supplementation, prior GI events, BMI, and female sex. Reaching a final MTX dose of ≥ 15 mg/week is associated with the use of folates as well as with prior GI events. A good response to MTX treatment is related to the DAS at baseline, the use of NSAIDs, male sex, and creatinine clearance.

The data from the RCT that we used were obtained by applying a treatment protocol designed to mirror clinical practice with MTX. Clinical trials are not the best way to draw conclusions about predicting toxicity, especially with respect to rare side effects. In this study we were interested in common toxicity limiting the use of MTX. The magnitude of the trial as well as its design makes it suitable to address the questions of the present study. One of the few points that prevents generalisation of our data to clinical practice is the exclusion of patients with a creatinine clearance < 50 ml/min. Although in routine care patients with impaired renal function are not likely to be treated with MTX, this has to be taken into account.

An increase in transaminase was reduced significantly by folates. This is in agreement with the findings of Shiroky *et al.*¹² The influence of folic acid on transaminase levels was not specifically mentioned in the studies by Morgan *et al.*^{14,15} In preceding studies a relation between obesity or weight and rise in transaminase or severe liver disease was found, which was confirmed by our observations.^{11,30} An explanation for this may be the association between obesity and a fatty liver, increasing the susceptibility to MTX related toxicity. In accordance with a meta-analysis on 496 patients by Felson, as well as a study on 469 patients by Bologna, we found no relation between age, renal function, and a rise in transaminase.^{8,9}

In contrast with the study by Shiroky, which showed a marked reduction of GI side effects due to folic acid supple-

mentation, our trial did not reveal a relation between either folic acid or folinic acid and GI side effects. Our data showed an association between prior GI events, a lower age, and diarrhoea. Bologna *et al.* also reported a lower incidence of GI side effects in the older age group,⁹ whereas in another study of 235 patients with RA treated with MTX GI symptoms were reported more frequently in the older age group.⁷ In both studies these GI side effects have not been specified in detail, so the part explained by diarrhoea is not known.

Hepatotoxicity and GI side effects were the main reason for MTX withdrawal and it is therefore not surprising that a relation between folate supplementation, BMI, prior GI events, and MTX withdrawal was found. No relation between age and MTX withdrawal was found. In accordance with a 13 year retrospective study of 144 patients with RA our study confirmed that MTX withdrawal was related to female sex.³ In contrast, our data did not show a relation between age and MTX withdrawal, which coincides with the results of the study by Bologna *et al.*⁹

The addition of folates increases the chances of reaching a higher MTX dose. This is probably determined by a reduction of side effects, but may also be due to a lower efficacy. With a history of prior GI events the chance of reaching a higher dose is smaller, which can be explained by the occurrence of GI side effects. Renal function and age were not related to the dose reached.

Anderson *et al.* studied factors influencing response to treatment in a meta-analysis of 1435 patients. In their multivariate analysis, disease duration as well as patient global assessment of disease activity were significantly related to treatment response.²³ In contrast with this, we found no relation between disease duration and efficacy, the mean disease duration being lower in our study. The assessment of disease activity in our study comprised apart from the patient's global assessment, the Ritchie articular index, the 44 joint count, and the erythrocyte sedimentation rate. The DAS combines these four variables. A good EULAR response is not easily achieved when the DAS is high at baseline. In accordance with the study of Anderson *et al.*, efficacy of MTX was better in men. Concomitant use of NSAIDs was associated with increased efficacy. A study by Cush *et al.* showed a positive effect of NSAIDs on disease activity.³¹ In contrast with others we found a relation between renal function and good response. The response was better in patients with a lower creatinine clearance. This was not explained by the MTX dose, but may be explained by a longer MTX exposure due to renal impairment.

CONCLUSIONS

Apart from the beneficial effect of folate supplementation on the occurrence of hepatotoxicity and MTX withdrawal due to toxicity, side effects were associated with BMI, prior GI events, and female sex. Prior GI events and a lower age are related to the occurrence of diarrhoea. Renal function (creatinine clearance ≥ 50 ml/min) was not associated with toxicity and MTX withdrawal due to toxicity.

Reaching a final dose of MTX of ≥ 15 mg/week is particularly related to folate supplementation and to a lack of prior GI events. This is probably explained by a reduction of toxicity. A good response to MTX treatment is mainly related to the DAS at baseline, and to a lesser extent to the use of NSAIDs, male sex, and creatinine clearance. Efficacy was not influenced by age.

As a result of this study a suggested approach for daily practice might be that in patients with RA, who do not have prior GI events or a high BMI and have a calculated creatinine clearance ≥ 50 ml/min, one can start with 15 mg/week MTX, provided that folates are added to the treatment.

Authors' affiliations

M Hoekstra, C J Haagsma, M A F J van de Laar, M W M Kruijsen, Department of Rheumatology, Medisch Spectrum Twente, Enschede, The Netherlands

A E van Ede, R F J M Laan, Department of Rheumatology, University Medical Centre Nijmegen, The Netherlands

T W J Huizinga, Department of Rheumatology, Leiden University Medical Centre, The Netherlands

REFERENCES

- 1 Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. *Arthritis Rheum* 1990;33:1449-61.
- 2 Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. *Arthritis Rheum* 1992;35:138-45.
- 3 Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. *J Rheumatol* 1998;25:238-42.
- 4 Alarcon GS, Tracy IC, Blackburn WD. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. *Arthritis Rheum* 1989;32:671-6.
- 5 McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. *J Rheumatol* 1993;20:1850-6.
- 6 Bologna C, Viu P, Picot MC, Jorgensen C, Sany J. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open retrospective, observational study. *Br J Rheumatol* 1997;36:535-40.
- 7 Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. *J Rheumatol* 1991;18:973-7.
- 8 Rheumatoid arthritis clinical trial archive group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. *J Rheumatol* 1995;22:218-23.
- 9 Bologna C, Viu P, Jorgensen C, Sany J. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. *Br J Rheumatol* 1996;35:453-7.
- 10 Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. *Arthritis Rheum* 1989;32:121-7.
- 11 Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. *Scand J Rheumatol* 1999;28:273-81.
- 12 Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 1993;36:795-803.
- 13 van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2001;44:1515-24.
- 14 Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 1990;33:9-18.
- 15 Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind placebo-controlled trial. *Ann Intern Med* 1994;121:833-41.
- 16 Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med* 1997;127:356-64.
- 17 Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Leslie AL, Cook NJ, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. *J Rheumatol* 1994;21:51-4.
- 18 Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. *J Rheumatol* 1995;22:1043-7.
- 19 Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. *J Rheumatol* 1997;24:2299-303.
- 20 Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. *Semin Arthritis Rheum* 1987;16:186-95.
- 21 Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. *Arthritis Rheum* 1996;39:272-6.
- 22 Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. *Arthritis Rheum* 1989;32:770-5.
- 23 Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. *Arthritis Rheum* 2000;43:22-9.
- 24 Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. *J Rheumatol* 1993;20:950-2.
- 25 Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. *J Rheumatol* 1988;15:1078-80.
- 26 Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. *J Rheumatol* 1989;16:313-20.
- 27 Seideman P. Methotrexate—the relationship between dose and clinical effect. *Br J Rheumatol* 1993;32:751-3.
- 28 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41.
- 29 van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum* 1996;39:34-40.
- 30 Brick JE, Moreland LW, Al Kwas F, Chang WW, Layne RD, DiBartolomeo AG. Prospective analysis of liver biopsies before and after methotrexate therapy. A prospective study with baseline and sequential biopsy samples. *Semin Arthritis Rheum* 1989;19:31-44.
- 31 Cush JJ, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. *Arthritis Rheum* 1990;33:19-28.